Supernus Pharmaceuticals Income Statement (2011-2026) | SUPN

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	141.33M	148.46M	159.05M	152.51M	170.05M	177.35M	167.33M	153.76M	135.56M	153.88M	164.31M	143.64M	168.32M	175.69M	174.16M	149.82M	165.45M	192.10M	211.57M
Cost of Revenue (Quarter)	25.03M	18.09M	16.99M	17.93M	20.46M	25.88M	22.95M	23.46M	21.09M	19.60M	19.63M	16.31M	17.92M	17.58M	26.10M	15.76M	16.83M	18.96M	23.01M
Gross Profit (Quarter)	116.30M	130.38M	142.06M	134.57M	149.59M	151.47M	144.37M	130.30M	114.47M	134.28M	144.69M	127.33M	150.41M	158.11M	148.06M	134.06M	148.63M	173.14M	188.56M
Operating items
Amortization - Intangibles (Quarter)	5.95M	6.01M	12.04M	20.60M	20.64M	20.64M	20.73M	20.00M	20.11M	21.20M	21.09M	20.10M	20.11M	19.49M	18.30M	19.79M	20.82M	24.30M	24.57M
Research & Development (Quarter)	15.46M	19.65M	21.08M	20.84M	16.39M	19.55M	17.77M	21.21M	24.38M	22.66M	23.35M	24.93M	26.18M	29.04M	28.65M	26.93M	22.11M	29.37M	27.83M
Selling, General & Administrative (Quarter)	69.53M	72.03M	101.73M	90.46M	100.48M	112.31M	73.97M	85.60M	86.78M	82.70M	81.28M	86.52M	85.90M	69.75M	79.41M	89.94M	93.55M	179.68M	122.39M
Other Operating Expenses (Quarter)	22.23M	24.17M	30.14M	39.24M	41.84M	47.01M	41.25M	41.78M	41.99M	40.39M	60.68M	35.35M	33.67M	36.05M	44.70M	43.21M	37.65M	43.29M	65.29M
Operating Expenses (Quarter)	107.22M	115.86M	152.95M	150.54M	158.71M	178.88M	132.99M	148.59M	153.15M	145.74M	165.31M	146.80M	145.76M	134.84M	152.75M	160.08M	153.31M	252.33M	215.51M
Operating Income (Quarter)	34.11M	32.60M	6.10M	1.97M	11.35M	-1.52M	34.33M	5.18M	-17.59M	8.14M	-1.00M	-3.15M	22.57M	40.84M	21.41M	-10.26M	12.14M	-60.23M	-3.94M
EBIT (Quarter)	34.11M	32.60M	6.10M	1.97M	11.35M	-1.52M	34.33M	5.18M	-17.59M	8.14M	-1.00M	-3.15M	22.57M	40.84M	21.41M	-10.26M	12.14M	-60.23M	-3.94M
Non-operating items
Non Operating Investment Income (Quarter)
Interest & Investment Income (Quarter)
Other Non Operating Income (Quarter)	2.59M	2.28M	-21.54M	14.70M	1.79M	2.80M	2.40M	5.35M	1.37M	1.75M	1.99M	3.40M	3.73M	4.10M	4.98M	4.42M	4.53M	2.28M	2.02M
Non Operating Income (Quarter)	-2.88M	2.28M	-21.54M	14.70M	1.79M	1.08M	2.40M	3.84M	0.46M	1.75M	-0.43M	3.40M	3.73M	4.10M	4.98M	4.42M	4.53M	2.28M	2.02M
Net income details
EBT (Quarter)	31.23M	28.96M	2.05M	14.72M	11.32M	-0.44M	35.14M	9.02M	-17.13M	9.89M	0.99M	0.24M	26.30M	44.94M	26.38M	-5.83M	16.67M	-57.95M	-1.91M
Tax Provisions (Quarter)	7.51M	7.40M	-0.39M	-10.90M	3.50M	-2.19M	9.63M	-7.90M	-16.30M	25.90M	-0.15M	0.12M	6.40M	6.40M	11.05M	6.00M	-5.83M	-12.84M	2.22M
Profit After Tax (Quarter)	23.73M	21.56M	2.44M	25.62M	7.87M	1.75M	25.48M	16.95M	-0.83M	-15.98M	1.18M	0.12M	19.92M	38.50M	15.33M	-11.83M	22.50M	-45.12M	-4.11M	-2.29M
Income from Continuing Operations (Quarter)	23.73M	21.56M	2.44M	25.62M	7.82M	1.75M	25.51M	16.92M	-0.83M	-16.01M	1.14M	0.12M	19.90M	38.54M	15.33M	-11.83M	22.50M	-45.12M	-4.13M
Consolidated Net Income (Quarter)	23.73M	21.56M	2.44M	25.62M	7.82M	1.75M	25.51M	16.92M	-0.83M	-16.01M	1.14M	0.12M	19.90M	38.54M	15.33M	-11.83M	22.50M	-45.12M	-4.13M
Income towards Parent Company (Quarter)	23.73M	21.56M	2.44M	25.62M	7.82M	1.75M	25.51M	16.92M	-0.83M	-16.01M	1.14M	0.12M	19.90M	38.54M	15.33M	-11.83M	22.50M	-45.12M	-4.13M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)	23.73M	21.56M	2.44M	25.62M	7.82M	1.75M	25.51M	16.92M	-0.83M	-16.01M	1.14M	0.12M	19.90M	38.54M	15.33M	-11.83M	22.50M	-45.12M	-4.13M
Additional items
EPS (Basic) (Quarter)	0.45	0.41	0.05	0.48	0.15	0.03	0.47	0.31	-0.02	-0.29	0.02	0.00	0.36	0.70	0.28	-0.21	0.40	-0.80	-0.07
EPS (Weighted Average and Diluted) (Quarter)	0.43	0.40	0.04	0.43	0.14	0.03	0.42	0.29	-0.02	-0.29	0.02	0.00	0.36	0.69	0.27	-0.21	0.40	-0.80	-0.07
Shares Outstanding (Weighted Average) (Quarter)	52.99M	53.19M	53.10M	53.33M	53.38M	53.52M	53.67M	54.38M	54.50M	54.50M	54.54M	54.80M	54.89M	54.98M	55.10M	55.86M	55.95M	56.55M	56.45M	57.65M
Shares Outstanding (Diluted Average) (Quarter)	54.60M	54.33M	54.36M	61.41M	61.40M	61.54M	61.68M	62.45M	54.50M	55.57M	55.51M	55.63M	55.72M	56.02M	55.96M	55.86M	56.69M	56.13M	56.45M
EBITDA (Quarter)	34.11M	32.60M	6.10M	1.97M	11.35M	-1.52M	34.33M	5.18M	-17.59M	8.14M	-1.00M	-3.15M	22.57M	40.84M	21.41M	-11.80M	12.14M	-60.23M	-3.94M	-2.50M
Interest Expenses (Quarter)	5.47M	5.92M	5.93M	1.94M	1.81M	1.72M	1.59M	1.50M	0.91M
Tax Rate (Quarter)	24.04%	25.55%	-19.06%	-74.03%	30.91%	493.92%	27.41%	-87.61%	95.15%	261.91%	-14.85%	48.97%	24.33%	14.24%	41.90%	-102.83%	-34.98%	22.15%	-115.99%

Research Tools

Supernus Pharmaceuticals Income Statement (2011-2026) | SUPN

Create an account

Sign In

Reset Password